Tag Archives: Pregnancy

I usually don’t trash talk, but….

 You should be concerned about the effects of asthma medication on the developing fetus; fortunately, birth defects are rare and often overstated, but you always have to maintain vigilance for new developments.
 
Why the concern about atresia? 
 

Maternal Asthma Medication Use May Cause Certain Birth Defects

Approximately 4% to 12% of pregnant women have asthma. Current clinical guidelines recommend that women with asthma maintain asthma therapy use during pregnancy. These medications act in 2 ways: as bronchodilators or anti-inflammatories. Few studies have examined the effects of maternal asthma medication use on birth defects.

The aim of this study by Lin and colleagues was to examine whether maternal asthma medication use during early pregnancy increases the risk for selected birth defects.  (Pediatrics. Published online January 16, 2012)

Study Synopsis and Perspective

A recent study found a statistically significant increase in the risk for isolated esophageal atresia, isolated anorectal atresia, and omphalocele in infants whose mothers used asthma medications within the month before conception or during the first 3 months of pregnancy.

Shao Lin, PhD, from the Center for Environmental Health, New York State Department of Health, Troy, and colleagues reported their study results in an article published online January 16 in Pediatrics.

The researchers used data collected for the National Birth Defects Prevention Study, an ongoing, multicenter, population-based, case-control study of the causes of birth defects that has been collecting data from 10 states in the United States since 1997 by conducting interviews with mothers and analyzing DNA obtained from cheek swabs from family members. That study includes both infants with 1 or more specified birth defects (diaphragmatic hernia, esophageal atresia, small intestinal atresia, anorectal atresia, neural tube defects, omphalocele, or limb deficiencies) and control infants without those birth defects.

For this study, the researchers analyzed data from a case group consisting of 2853 live births, stillbirths, or elective terminations with estimated dates of delivery from October 1, 1997, through December 31, 2005, and with 1 or more of the identified birth defects. The control group comprised 6726 infants born alive and without birth defects during the same period, randomly selected from birth hospital information or birth certificates.

Dr. Lin’s team concentrated on periconceptional use of anti-inflammatory medications, bronchodilators, or both. They defined exposure as use of asthma medication once or more from 1 month before conception through the third month of gestation. Mothers who described their medication use as only “as needed” and who could not provide an exact time frame for use were excluded from the study.  (This is a good study design to exclude these patients…doesn’t give you biased results for minimal exposure)

The study found a statistically significant association between isolated esophageal atresia and bronchodilator use only (adjusted odds ratio [aOR], 2.39; 95% confidence interval [CI], 1.23 – 4.66). The aORs for esophageal atresia and anti-inflammatory use only (aOR, 1.61; 95% CI, 0.69 – 3.76) and for use of both bronchodilators and anti-inflammatory medications (aOR, 2.93; 95% CI, 0.88 – 9.75) were elevated, but were not statistically significant.

There was a statistically significant increase in the risk for isolated anorectal atresia associated with anti-inflammatory use only (aOR, 2.12; 95% CI, 1.09 – 4.12).

Use of both bronchodilators and anti-inflammatory medications was associated with a statistically significant increase in the risk for isolated omphalocele (aOR, 4.13; 95% CI, 1.43 – 11.95).

The results are not all bad however.  The medications studied were not significantly associated with 6 other birth defects studied (neural tube defects, anencephaly, spina bifida, small intestinal atresia, limb deficiency, and diaphragmatic hernia).

The researchers performed a stratified analysis by time of medication use, using the periconceptional period and the period from the fourth through ninth month of gestation. The positive associations were found only in infants of women who took the medications during the periconceptional period, and not in infants whose mothers took the medications only in the fourth through ninth months of pregnancy. 

My comment—>by the time you know you’re pregnant, you’ve had the exposure!

The authors write that from 60% to 67% of mothers of infants with esophageal atresia, anorectal atresia, and omphalocele used bronchodilators during their entire pregnancy, although these data were not shown.

This is a key point–“With the interview information available for analysis, we were unable to distinguish between the effects of asthma and those of asthma medications; however, we did observe that mothers with possible indicators of uncontrolled asthma or severe asthma episodes (eg, use of multiple bronchodilators) were at higher risk for delivering a child with 1 of the defects studied than those who used 1 bronchodilator,” the authors write.

“When regular use of bronchodilators is required, an activated inflammatory process is implied; thus, use of bronchodilators throughout pregnancy might indicate that these mothers had frequent or ongoing inflammatory exacerbations during pregnancy,” they add.

Noting the importance of controlling asthma during pregnancy, the authors write, “The current clinical guidelines and specific recommendations for aggressive asthma management during pregnancy should remain unchanged.”

“Given the low baseline prevalence of these defects, if the observed association proved to be causal, the absolute risks of asthma medications on these rare defects would be small,” they conclude.

The study was supported by the Centers for Disease Control and Prevention. The authors have disclosed no relevant financial relationships.

Clinical Implications

  • Clinical guidelines recommend that women with asthma maintain asthma medication use during pregnancy.
  • In the current study, positive associations were observed for anorectal atresia, esophageal atresia, and omphalocele and maternal periconceptional use of asthma medications, but not for other birth defects studied.

You must want to know how to treat esophageal atresia?

Advertisements

Help….my face is swelling!

 

 

New Guidelines Detail Hereditary Angioedema Management in Women

Angioedema is a BIG problem in emergency rooms across the country and Tulsa is no exception!  Most treatment protocols use antihistamines (Benadryl) along with steroids. aughhh! 

 

.  She has some very common frustrations with this condition.  The REASON antihistamines & prednisone often don’t work with angioedema is because the mediator is bradykinin, not histamine! 

An international panel of gynecologists and geneticists has issued practical guidelines for managing women with hereditary angioedema caused by C1 inhibitor deficiency, or HAE-C1-INH.The condition affects between one in 10,000 and one in 50,000 individuals, and estrogen is known to worsen the course of the disease.But little information has been published on how to manage gynecologic/obstetric events in women with HAE-C1-INH, the panel writes in its report, published in the Journal of Allergy and Clinical Immunology.

Effective acute treatments include plasma-derived human C1 inhibitor concentrate (pdhC1INH), icatibant acetate, ecallantide, and recombinant human C1 inhibitor (rhC1INH), the doses of which are the same during pregnancy. PdhC1INH is recommended as first-line therapy in pregnancy.

Short-term prophylaxis (before invasive medical, surgical, or dental procedures or other events that could precipitate edematous attacks) can be provided by pdhC1INH, attenuated androgens, tranexamic acid, and fresh frozen plasma, but pdhC1INH is the treatment of choice during pregnancy.

The same drugs can be used for long-term prophylaxis, but attenuated androgens are contraindicated during pregnancy and tranexamic acid during pregnancy is medically indicated only when pdgC1INH is unavailable, Dr. Teresa Caballero from Hospital La Paz Health Research Institute in Madrid and colleagues note.

Because of the contribution of estrogen to worsening of HAE symptoms, its use for contraception and menopause should be avoided.

For similar reasons, antiestrogens like tamoxifen that may have some agonistic effects on estrogen receptors should be avoided in breast cancer patients. If possible, attenuated androgens should also be avoided as prophylaxis in these women.

The guidelines also address special features of HAE-C1-INH treatment in female patients, such as genetic counseling, infertility, abortion, lactation, and endometrial cancer.

SOURCE: http://bit.ly/AxvhMc

J Allergy Clin Immunol 2011.